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Factor XIIIA (FXIIIA) is a transglutaminase that crosslinks intra- and extracellular protein 
substrates. FXIIIA is expressed as an inactive zymogen, and during blood coagulation, it is 
activated by removal of an activation peptide by the protease thrombin. No such proteolytic 
FXIIIA activation is known to occur in other tissues or the intracellular form of FXIIIA. For 
those locations, FXIIIA is assumed instead to undergo activation by Ca2+ ions. Previously, we 
demonstrated a monomeric state for active FXIIIA. Current analytical ultracentrifugation and 
kinetic experiments revealed that thrombin-activated FXIIIA has a higher conformational 
flexibility and a stronger affinity toward glutamine substrate than does nonproteolytically 
activated FXIIIA. The proteolytic FXIIIA activation was further investigated in a context of 
fibrin clotting. In a series of fibrin crosslinking assays and scanning electron microscopy studies 
of plasma clots, the activation rates of FXIIIA V34X variants was correlated with the extent of 
fibrin crosslinking and incorporation of nonfibrous protein into the clot. Overall, the results 
suggest conformational and functional differences between active FXIIIA forms, thus expanding 
the understanding of FXIIIA function. Those differences may serve as a basis for developing 




Blue Text:  Changes made to manuscript based on reviewer comments 
Red Text:  Additional changes introduced yesterday after comparing with Cover Letter and 
Referee Responses 
Purple Text:  Final set of changes made.   





Factor XIIIA (FXIIIA) has been a subject of medically related research for almost a 
century. Perhaps the most studied is the role of FXIIIA in crosslinking the fibrin network, 
making it more mechanically stable and resistant to fibrinolysis. As physiological knowledge on 
FXIII expands, it becomes apparent that beyond serving as a key player of the blood coagulation 
system, FXIIIA functions in wound healing, bone tissue dynamics, signaling, and other areas [1-
10].  
FXIIIA is a transglutaminase that crosslinks protein substrates via an isopeptide bond in a 
Ca2+-dependent manner. FXIIIA is expressed as an inactive zymogen and in plasma, it circulates 
in a heterotetrameric complex with carrier FXIIIB (A2B2). During blood coagulation, plasma 
FXIII is activated by thrombin-mediated removal of N-terminal activation peptides (AP) from 
the A-subunits followed by binding of Ca2+ and dissociation of the B-subunits [11]. The active 
FXIIIA then introduces covalent crosslinks between polymerizing fibrin molecules and 
incorporates other proteins into the network, ultimately increasing mechanical stability of the 
resulting clot and its resistance to fibrinolysis [12]. 
Intracellularly, such as in platelets, monocytes, and macrophages, FXIII exists as an A2-
homodimer and is thought to undergo slow nonproteolytic activation in the presence of low 
available Ca2+ concentrations [13-15]. In this physiological compartment, FXIIIA is present in 
the cytoplasm, associates with membrane [10, 16], and even appears in the nucleus [17]. 
Activation and translocation of FXIIIA from the platelet cytoplasm to the platelet membrane 
does not require thrombin dependent steps. The minor amount of transglutaminase activity 
observed in a subsequent fibrin-platelet environment is proposed to be due to non-proteolytic 




of cytoskeletal proteins and chromatin remodeling [9]. FXIIIA is also secreted by osteoblasts 
into the extracellular matrix (ECM) [19], where it contributes to formation of the ECM itself and 
remodeling of the bone tissue [6, 16, 20]. Although a 37 kDa proteolytic fragment of FXIIIA was 
proposed to exist in the bone ECM [19, 21], it was later identified as transaldolase-1 that was 
immunoreactive with anti-FXIIIA antibody [22]. Thus, no evidence of proteolytic FXIIIA 
activation in bone ECM currently exists. However, with available ECM Ca2+ concentrations as 
high as 25 – 40 mM [23, 24], bone ECM FXIIIA may be activated by Ca2+ without proteolysis.  
FXIIIA has also been implicated in pathological conditions such as thrombosis [25], 
inflammation, oncogenic events and diabetes [10], and arthritis [26]. Although FXIIIA is 
involved in an array of intra- and extracellular events, an in-depth understanding of FXIIIA 
activation and function in different physiological environments is lacking.  With more 
knowledge, therapeutic strategies might be developed to target zymogen FXIII or activated 
FXIIIA under specific physiological or pathological conditions. Previously, we studied the 
oligomeric states of FXIIIA in different solution conditions [27]. We found that FXIII A2-
homodimer dissociates into monomers during activation by thrombin. Cleavage of a single AP 
on the dimeric FXIII A2 was sufficient to promote dissociation and full activity of the A-
subunits. Nonproteolytic activation by high Ca2+ concentration also resulted in subunit 
dissociation, however, these species possessed lower activity [27].  
In the current project, we hypothesized that in different physiological compartments such 
as blood plasma, intracellular, and bone ECM, activation of FXIIIA may result in 
conformationally different enzymatic species. We focused on probing functional implications of 
thrombin activation of FXIIIA in the presence of low mM Ca2+ (mimicking conditions in plasma, 




mM Ca2+ (intracellular activation, FXIIIA°,low), and activation in the presence of high (≥β5 mM) 
Ca2+ (bone ECM, FXIIIA°,high). We demonstrated an overall slower rate of FXIIIA 
nonproteolytic activation, as compared to the thrombin-mediated cleavage. Moreover, enzymatic 
activity assays revealed differences in the substrate affinities of FXIIIA* and FXIIIA°,high.  Using 
a fibrin clotting model in a pure protein system as well as in plasma, we further examined how 
proteolytic activation of FXIIIA V34X variants can be used to control rate of fibrin crosslinking 
function and also influence fibrin clot structure. In summary, our results support proposed 
conformational differences between FXIIIA active forms in different physiological 
environments. Finally, we discuss how these differences may serve as a basis for differential 




Solution properties of FXIIIA species in different activation conditions. Previously in a 
series of AUC experiments, we demonstrated that zymogenic FXIII A2 homodimer completely 
dissociates into monomers upon proteolytic and nonproteolytic activation [27]. In the current 
work, we employed sedimentation velocity AUC to compare the solution dynamics of FXIIIA 
under different conditions. FXIIIA was activated in the presence of 100 mM Ca2+ (FXIIIA° ,high) 
or by thrombin in the presence of 4 mM Ca2+ (FXIIIA*). The high 100 mM Ca2+ helped to 
quickly obtain uniform, monomeric FXIIIA°,high species [27]. As a control for a possible divalent 
cation-mediated ionic strength effect, additional samples of FXIIIA* were supplemented with 
100 mM Mg2+. Unlike Ca2+, this divalent cation does not efficiently support dissociation or 
activity of FXIII A-subunits [27]. To eliminate possible differences in sample handling between 




resulting sedimentation coefficient distributions are presented in Fig. 1A. In the presence of 100 
mM Ca2+ (FXIIIA° ,high, trace i), we observed a tall narrow peak, approximately 1 S unit in width. 
As reported previously [27], significant precipitation occurred in FXIIIA* samples during 
centrifugation, and the sedimentation distribution peak was much broader, approximately 2 S 
(trace ii). In the presence of 4 mM Ca2+ nd 100 mM Mg2+ (trace iii), the FXIIIA* sedimentation 
peak was also broad (2 S). 
Sedimentation coefficients represent the velocity of particle sedimentation (in the present 
case, FXIIIA molecules) in a centrifugal field [28]. Apart from the physical characteristics of a 
solution, which are accounted for in data analysis, the sedimentation coefficient ultimately 
depends on the weight and shape of those particles. Thus, in samples of monomeric FXIIIA, it is 
the diversity of shapes (conformations) that constitutes the sedimentation distribution. The broad 
sedimentation distribution peak indicates that FXIIIA* is more conformationally heterogeneous 
in solution than FXIIIA°,high, and this heterogeneity is retained in the presence of 100 mM Mg2+.
This observation suggests that Ca2+ exerts a specific effect on FXIIIA conformation.   The 
related divalent cation Mg2+ cannot mimic this property and, moreover, the conformational effect 
is not due to a simple increase in ionic strength.   
To examine FXIIIA nonproteolytic activation at lower, more physiological Ca2+ 
concentrations, FXIIIA was incubated in the presence of 4 mM Ca2+ for 30 min – 96 h, followed 
by AUC. Unexpectedly, progressive precipitation was observed in these samples of FXIIIA°,low, 
very similar to the solution behavior of the thrombin-activated FXIIIA*. In previous 
experiments, we found addition of 5% DMSO promoted solubility of FXIIIA* over the course of 
a few hours [27]. However, 4 mM Ca2+-activation required longer incubation periods to obtain 




The actual amount of protein in solution was assessed via absorbance at the start of an AUC 
experiment (Fig. 1B, insert). The plot in Fig. 1B (open circles) then represents the amount of 
monomeric FXIIIA as a fraction of soluble protein in each sample. The most observed 
dissociation of the A-subunits, ~ 65%, was observed after 72 h incubation. Such nonproteolytic 
activation of FXIIIA may proceed intracellularly, although much slower than observed in the 
presence of 4 mM Ca2+, as intracellular Ca2+ is actually maintained at nanomolar to micromolar 
levels. Furthermore, the aggregation propensity of FXIIIA°,low suggests its relatively short 
lifetime, in a good agreement with a study by Muszbek et al. [13], reporting a small, 6.5% of 
FXIIIA population within platelets being active. 
In order to mimic activation conditions of bone tissue ECM, FXIIIA was incubated in the 
presence of higher, 25 mM Ca2+ for 30 min – 6 h (Fig. 1B, filled circles). The dissociation of the 
dimeric zymogen under these conditions occurred faster than at 4 mM Ca2+ (80% at 6 h of 
incubation) and, analogous to activation by 100 mM Ca2+, no precipitation of these FXIII°,high 
species was observed (Fig. 1B, panel on the right). Thus, the current results indicate overall 
slower activation of FXIIIA by Ca2+ alone, as compared to the proteolysis by thrombin resulting 
in full dissociation of FXIIIA within minutes. High (≥β5 mM) Ca2+ levels reduce conformational 
heterogeneity and aid in maintaining stability of activated FXIIIA species in solution.  
 
A model system of FXIIIA proteolytic activation kinetics. To better understand 
FXIIIA function in different physiological contexts, the peculiarities of individual activation 
environments need to be considered. Due to highly regulated calcium homeostasis in the body, 
nonproteolytic activation pathways leading to FXIIIA°,low and FXIIIA°,high likely operate on an 




ECM.  Faster activation may then be achieved when higher Ca2+ concentrations are encountered 
as part of certain physiological or pathological processes.  In blood plasma, where Ca2+ 
concentration is maintained at a low 1.5 mM, such constitutive generation of FXIIIA°,low is 
prevented by association of FXIIIA with the inhibitory FXIIIB [15]. Under exigent cases such as 
bleeding, the proteolytic removal of AP facilitates fast FXIIIA activation. The concomitant use 
of the serine protease thrombin to activate FXIIIA and also convert fibrinogen to polymerizing 
fibrin adds complexity to this clotting mechanism.  [29]. As a result, the kinetics of FXIIIA* 
generation has a significant impact on the functional outcome of the clotting process. 
To explore this outcome, we generated and expressed FXIIIA variants with different 
amino acid residues at position 34 of the FXIII activation peptide. These variants differ in their 
rate of cleavage by thrombin [30] (Fig. 2A). The current studies provided the first testing of AP 
residues F34 and W34 on FXIIIA proteolytic activation and resulting transglutaminase function. 
Using an extended range of FXIII activation rates, comparisons could be made with the naturally 
occurring V34 and L34.   The FXIIIA AP variants were combined with human FXIII-free 
fibrinogen and clotting was initiated by addition of thrombin and Ca2+. As expected, the rate of 
FXIIIA proteolytic activation determined development of FXIIIA* crosslinking activity (Fig. 
βB). The fastest cleaved FXIIIA Lγ4 generated both け–け and higher molecular weight (HMW) 
fibrin species already at an early stage (5 min) of the experiment. Slow cleavage of FXIIIA W34 
by thrombin resulted in the slowest appearance of け–け and very little HMW crosslinks. 
Interestingly, F34 FXIIIA is cleaved by thrombin slightly slower than V34 variant (Fig. 2A); 
however, both variants crosslinked fibrin to a similar extent. This effect may be explained by the 
fact that the cleavage of a single AP on dimeric FXIIIA zymogen results in dissociation and 




competition of fibrinogen and FXIIIA for thrombin may have further masked the difference in 
V34 and F34 cleavage rate observed in the absence of fibrinogen. Th  four full-length FXIII 
V34X variants could thus be used to control the timing of appearance of FXIII activity without 
diminishing thrombin-mediated conversion of fibrinogen to fibrin or altering the clot gelation 
dynamics. Moreover, the extent of crosslinking before initiation of fibrinolysis could be 
documented.  
To further probe the functional impact of FXIIIA activation rate, three AP variants that 
demonstrated different degrees of fibrin crosslinking (L34, V34, and W34) were introduced into 
FXIIIA-deficient murine plasma, and clotting was initiated by addition of thrombin and Ca2+. 
The murine plasma system was already well established for introducing and screening FXIII 
V34, V34L, and/or G33A based clotting effects [32-34].  The resulting clots were imaged by 
SEM and representative photographs are shown in Fig. 3. Clots formed in the presence of 
FXIIIA better retained their three-dimensional structure due to FXIIIA-mediated covalent 
crosslinking of the fibrin fibers. Interestingly, we observed nonfibrous protein networks 
embedded to different degrees within the crosslinked fibrin clots. The least amount occurred with 
the FXIII AP- variant W34 (slower proteolytic activation) and the most with the L34 (faster 
activation). Such networks were uniformly distributed and must be covalently crosslinked within 
the clot, since they remained even after extensive washing during SEM sample preparation. The 
nonfibrous material may represent unpolymerized fibrin or other plasma proteins and is expected 
to contribute to overall clot penetrability and mechanical and fibrinolytic stability. 
 
Catalytic comparisons of FXIIIA* and FXIIIA° ,high  Previously, when using a standard 




compared to FXIIIA* [27]. In the current work, we attempted to probe this difference in more 
detail. The transglutaminase activities of FXIIIA activated by thrombin in the presence of 4 mM 
Ca2+ (FXIIIA*) or by 100 mM Ca2+ (FXIIIA° ,high) were compared in a series of enzymatic 
evaluations. Since it was impossible to isolate stable, uniformly monomeric species of FXIII°,low 
on a reasonable time scale, this FXIIIA form was not included in catalytic comparisons.  
To assess the catalytic differences between FXIIIA* and FXIII°,high, we employed a 
spectrophotometric assay using K9 peptide (1LGPGQSKVIG10) as a glutamine substrate and 
chromogenic DMPDA as second, amine substrate. Unlike the ammonia release assay, the 
transglutaminase reaction was now monitored directly at its second step, formation of a cross-
linked product. An apparent Km for K9 peptide was almost two-fold lower for FXIIIA*, 
compared to FXIIIA°,high. This lower Km indicated better interaction of the FXIIIA* enzymatic 
form with the glutamine substrate (Fig. 4A). On the other hand, FXIII°,high demonstrated a 
slightly stronger Vmax value suggesting that once saturated with the glutamine donor K9, 
FXIII° ,high provides faster substrate turnover than FXIIIA*. Thus, the observed individual kinetic 
parameters further corroborate proposed conformational/dynamic differences between FXIIIA* 
and FXIIIA°,high. 
We next conducted a series of SDS-PAGE assays to monitor FXIIIA-catalyzed 
crosslinking of a lysine mimic monodansylcadaverine (MDC) to a glutamine donor fibrinogen 
gC (βγγ-425). The dansyl moiety of MDC provides a fluorescent tag on the protein and once the 
gC band is resolved on SDS-PAGE, the crosslinking reaction can be monitored by fluorescence 
of that band. gC represents a physiological FXIIIA protein substrate and contains three reactive 
glutamines [36]. While four lysine residues are present in the gC (βγγ-425) sequence, no 




detected even at high gC concentrations (Fig. 4B, panel iv). At 5 µM gC concentration, the 
extent of MDC incorporation catalyzed by FXIIIA* was greater than by FXIIIA°,high (Fig. 4B, 
panel i). Interestingly, increased monovalent ionic strength has been shown to promote higher 
FXIIIA activity [13, 15, 37, 38]. To rule out the possibility of an inhibitory effect of divalent 
ionic strength, the Ca2+ concentration in the crosslinking reaction was lowered from 100 mM 
down to 25 mM Ca2+ (Fig. 4B, panel ii). MDC crosslinking to gC by FXIIIA°,high was essentially 
the same regardless of Ca2+ concentration in the crosslinking reaction mix, and in both cases, the 
FXIIIA° ,high activity was lower than that catalyzed by FXIIIA*. When gC concentration was 
raised to 40 µM, the difference between crosslinking activity of FXIIIA* and FXIIIA°,high 
became indistinguishable (Fig. 4B, panel iii) .  Overall, the results obtained with the short K9 
peptide and a larger, more physiological gC substrate, suggest that FXIIIA* interacts with the 





Factor XIII activity has been reported in a variety of intra- and extracellular physiological 
environments and has been implicated in numerous pathological events. Being the final player of 
the coagulation cascade, FXIIIA has been recognized as a promising target for novel 
anticoagulant agents, with a prospect of fewer side effects [25, 39-41]. When implementing new 
coagulation management regimes, it may be desirable not to affect FXIII function in 
nonhemostatic events. On the other hand, those nonhemostatic functions may themselves present 
therapeutic interest. It is important to keep in mind that FXIII is activated either proteolytically 




pharmaceutical intervention approaches, critical new knowledge on these two FXIII activation 
strategies and their subsequent functional properties is needed.  
Using AUC in previous work, we demonstrated dissociation of the FXIII A2 dimer upon 
activation and that it is the monomeric FXIIIA that is catalytically competent [27]. In the curr nt 
project, we investigated and compared dynamic and functional implications of proteolytic and 
nonproteolytic FXIIIA activation pathways. While thrombin-mediated proteolysis resulted in full 
dissociation of the A-subunits within minutes, activation by Ca2+ lone at physiological 
concentrations proceeded slower and took hours. Due to highly regulated Ca homeostasis, 
however, this activation pathway may operate constantly, thus providing constitutive FXIII 
activity within cells and ECM.  
In contrast to FXIIIA* and FXIIIA°,low, nonproteolytic activation in the presence of high 
(≥β5 mM) Ca2+ did not result in aggregation of FXIIIA°,high species. Increased Ca2+ 
concentration was shown before to stabilize active FXIIIA in solution [31], and in current AUC 
experiments, we correlated higher Ca2+ levels with reduced conformational heterogeneity of 
FXIIIA° ,high, as compared to FXIIIA*. The poor solubility of FXIIIA°,low may suggest partial 
conformational similarity with FXIIIA*. However, the slow appearance of this form has limited 
its isolation and characterization in the current study. 
In our enzymatic evaluations, FXIIIA* had an almost two fold lower Km for the 
glutamine substrate than had FXIIIA°,high, thus suggesting stronger interaction of FXIIIA* with 
that substrate. On the other hand, FXIIIA°,high provided faster reaction turnover upon saturation 
with the glutamine donor. It is well known that the transglutaminase reaction proceeds through a 
mechanism involving addition of Q (glutamine) and K (amine or lysine) substrates. That is, the 




Therefore, this faster turnover by FXIIIA°,high may be due to better interaction with the K-
substrate and faster release of the crosslinked product.  
In early work, Lewis with coworkers [43] reported that each A-subunit of plasma 
zymogen FXIII A2B2 binds a Ca
2+ ion with 100 µM KD. Hornyak et al. [44] later demonstrated 
that another Ca2+ ion is required by each A-subunit to dissociate from the B-subunits and to 
expose catalytic cysteines. Stieler with coworkers [40] recently crystallized FXIIIA°,high with a 
covalently bound Q-mimic inhibitor, providing the first molecular structure of active FXIIIA. 
Besides the previously observed first, zymogenic Ca2+ site [45], the Stieler research group 
elegantly demonstrated the functional significance of two additional sites. In particular, 
development of the 2nd Ca2+ site brought about conformational changes in the FXIIIA molecule 
to initiate formation of a hydrophobic pocket for the K-substrate entrance. This site is the same 
as that presumed by Hornyak [44] to promote exposure of the reactive thiol on A-subunits. 
Coordination of the 3rd Ca2+ was proposed by Stieler et al. [40] to conclude formation of the 
hydrophobic pocket and to facilitate binding of the K-substrate.  
Since the addition of Q and K is sequential and the crystal structure presented by Stieler 
et al. [40] depicts a covalent FXIIIA–Q-substrate intermediate rather than a free enzyme, we 
entertain an idea that the 3rd site for Ca2+ is filled upon binding of the Q-substrate. Whether 
binding of Ca2+ at the 3rd site precedes binding of the K-substrate or vice versa, is open to 
speculation. It seems plausible that at relatively low Ca2+ levels coordination of this 3rd site and 
completion of the hydrophobic pocket is dependent on the availability of the K-substrate. Such a 
possibility is consistent with the fact that in the absence of K-substrate, a water molecule acts as 
an acyl acceptor resulting in net deamidation of the glutamine to glutamate [46]. Intriguingly, the 




demonstrated to be much lower than that for transamidation (crosslinking) [47], further 
supporting this possibility for a homologous FXIIIA. 
In conditions where Ca concentrations are relatively high, such as in bone ECM, the 3rd 
FXIIIA Ca2+ site may already be saturated even in a free enzyme, prior to the Q-substrate 
binding. Our kinetic results suggest that this saturation facilitates a conformation (FXIIIA°,high) 
that has a weaker affinity for the Q-substrate (indicated by higher Km in the current study) but 
provides faster reaction turnover, than FXIIIA* (higher observed Vmax). In addition to its 
stabilizing role observed in our AUC experiments, the FXIIIA°,high conformation may also favor 
transamidation of the protein substrates over deamidation in acidic conditions of the bone ECM. 
Thus far, the FXIIIA* form has been elusive from crystallographic efforts and also a 
challenging subject of solution experiments. The current studies effectively demonstrate that 
conformational differences do exist between FXIIIA* and FXIII°,high.  As mentioned before, the 
crystal structures of non-proteolytically activated FXIII°,high in complexes with inhibitors are 
available from the Stieler group (PDB 4KTY, 5MHM, 5 MHN, 5MHO).  It would thus be 
feasible to screen for pharmaceutical candidates that confer specificity to FXIIIA°,high and 
eliminate those affecting the FXIIIA*. Should this orthosteric design fail, a search for allosteric 
effectors may be more successful [41]. Previous studies in our group involving chemical 
modification and hydrogen-deuterium exchange suggested better solvent accessibility of the く-
sandwich region of FXIIIA*, while く-barrel 1 was more solvent-exposed in FXIIIA°,high [48, 49]. 
These local structural differences may serve as a starting point for allosteric targeting of FXIIIA. 
Prior studies have shown that increasing levels of FXIII A* affect the rate and extent of 
fibrin crosslinking [12, 33, 50].  Taking this property into consideration, the fibrin clot network 




we showed that the FXIII V34X variants (L34, F34, and W34) influenced such FXIIIA* 
generation rates and in response affected fibrin crosslinking. Faster proteolytic activation (and 
hence, higher amount of FXIIIA*) during blood coagulation resulted in a greater extent of fibrin 
crosslinking and incorporation of other proteins into the clot (FXIII L34>V34,F34>W34). The 
current results effectively complement FXIII activation peptide models examined by Duval and 
coworkers.  Their studies focused on A34, L34, M34 along with surrounding FXIII AP residues 
[32]. Our focus has been on fast activing L34 versus aromatic V34X substitutions that are well 
tolerated by the anticoagulant thrombin W215A species [30]. Thus, therapeutic strategies to 
specifically limit thrombin’s ability to activate FXIIIA and/or fibrinogen, may be promising.  
The tunable FXIII-based 34XVPRtG38 amino acid sequence might also be employed as a prodrug 
linker.  Thrombin-dependent cleavage of the linker sequence would release the pharmaceutical 
agent at a desirable rate and specifically at the clotting site. This approach would also ensure that 
neither FXIIIA°,low nor FXIIIA°,high are affected. 
Overall, the presented research expands the understanding of the functional outcomes of 
FXIII activation pathways. Based on our previous and current results, we offer the following 
model: nonproteolytic FXIIIA activation proceeds relatively slow, but constantly. High mM Ca2+ 
levels, such as in bone ECM, stabilize the FXIIIA°,high form and provide its constitutive activity 
as part of the tissue remodeling processes. By contrast, thrombin-mediated AP-removal 
facilitates binding of Ca2+ at its low level in plasma, thus promoting fast buildup of FXIII 
crosslinking activity. The resultant FXIIIA* species have higher affinity towards glutamine 
substrates and respond even to low concentrations of these substrates, ensuring clot-stabilizing 
function during blood coagulation. At the same time, the tendency of FXIIIA* to aggregation 




in conformationally different FXIIIA forms, thus providing a possible basis for developing 
therapeutic strategies for compartment-specific management of FXIIIA function. 
 
EXPERIMENTAL PROCEDURES 
Materials – Recombinant yeast expressed FXIIIA was a gift from the late Dr. Paul Bishop 
(Zymogenetics, Seattle, WA, USA). Recombinant human thrombin was generously provided by 
Dr. Enrico Di Cera and Dr. Leslie Pelc (St. Louis University, MO, USA). Bovine thrombin was 
purchased from Sigma-Aldrich (USA). Human FXIII-free peak 1 fibrinogen was purchased from 
Enzyme Research Laboratories (South Bend, IN, USA). Murine plasma was obtained from mice 
lacking the FXIII catalytic A subunit (FXIII A-/-) [26, 51]. Such FXIII-deficient mice were 
engineered to be missing the FXIII A subunits but still express the FXIII B subunits. The e mice 
were maintained at the Cincinnati Children’s Hospital Medical Center animal care facility. All 
studies involving the use of animals were approved by the Cincinnati Children’s Hospital 
Medical Center Institutional Animal Care and Use Committee. Cincinnati Children’s Hospital is 
an AAALAC accredited institution. Thrombin inhibitor D-phenylalanyl-prolyl-arginyl 
chloromethyl ketone (PPACK) was purchased from Haematologic Technologies (Essex Junction, 
VT, USA). A transglutaminase glutamine substrate peptide K9 (1LGPGQSKVIG10) was 
synthesized by New England Peptide (Gardner, MA, USA).  All other reagents were of the 







AUC studies of FXIIIA – Molar concentration in this work refers to A-subunits as opposed to 
A2-dimers of FXIIIA. 2 µM zymogen FXIIIA was incubated in borate buffer (20 mM boric acid, 
pH 7.8, 150 mM NaCl) in the presence of 25 – 100 mM CaCl2 for 30 min – 6 h at 37 °C. FXIIIA 
was also incubated in the borate buffer at a lower 4 mM CaCl2 for 30 min – 96 h. To achieve 
better solubility of FXIIIA under these conditions, the 4 mM Ca2+-samples were supplemented 
with 5% DMSO. For proteolytic activation, 2 µM FXIIIA was incubated in the borate buffer 
with bovine thrombin (3.5 NIH units/ml) and 4 mM CaCl2 for 30 min at 37 °C, followed by 
inhibition of thrombin with 760 nM PPACK. In addition to 4 mM CaCl2, some samples of the 
proteolytically activated FXIIIA were supplemented with 100 mM MgCl2. 
A detailed description of AUC experimental parameters can be found in [27]. Briefly, 
samples of activated FXIIIA were subjected to sedimentation velocity AUC in an Optima XL-A 
ultracentrifuge (Beckman Coulter) at 20 °C and 50,000 rpm. Data were analyzed using the 
program SEDFIT (www.analyticalultracentrifugation.com), and experimental sedimentation 
coefficients were corrected based on the measured density and viscosity of the buffer, thus 
allowing direct comparison of results obtained with different experimental conditions. Analytical 
runs were performed with two independent samples for each condition examined. Co trol studies 
repeated in the current project yielded Sedimentation Coefficient values that were highly 
comparable.  
 
Expression and purification of FXIIIA V34X variants and Fibrinogen gC (233-425) – 
pGEX plasmid vectors encoding GST-tagged FXIIIA V34 and GST-tagged fibrinogen gC (233-
425) were employed [52]. Single amino acid V34X substitutions (L, F, or W) were introduced 




The expression vectors were transformed into E. coli BL21 (DE3) Gold cells and proteins were 
expressed using auto-inducing media [53]. Using an AKTA Prime FPLC, GST-tagged proteins 
were purified by affinity chromatography on a GST-trap column (GE Healthcare, USA) system. 
Target proteins were cleaved from the GST-tag by in-column digestion with PreScission protease 
and eluted with tris buffered saline (TBS, Tris Acetate 50 mM, pH 7.4, NaCl 150 mM). The 
purity was assessed using SDS-PAGE, and molar concentration was determined from absorbance 
readings at β80 nm using i = 1β5710 M−1cm−1 for V34, F34, L34 FXIIIA variants and 131210 
M−1cm−1 for Wγ4 FXIIIA. An i = 41480 M−1cm−1 was applied for fibrinogen gC (βγγ-425). 
These extinction coefficients were calculated using Protparam tool (www.expasy.org). 
 
Fibrin crosslinking in the presence of FXIIIA V34X variants – Human FXIII-free fibrinogen 
(1 mg/ml), a recombinant FXIII AP variant (V34, L34, F34, or W34, 50 nM), and recombinant 
human thrombin (12 nM) were incubated in a 20 µL TBS containing 2.5 mM CaCl2 at 37 °C. At 
each time point (5 – 60 min), the reaction was quenched by addition of 10 µL of reducing sample 
loading buffer followed by boiling for 5 min, resulting in full solubilization of formed clots. 
Samples were then subjected to SDS-PAGE on an 8% gel. These fibrin crosslinking reactions 
were performed three independent times, with essentially the same results. 
 
SEM analysis of plasma clots formed in the presence of FXIIIA V34X variaants – A 
recombinant FXIII AP variant (L34, V34, or W34, 100 nM final concentration) was administered 
into citrated plasma from FXIIIA-deficient mice. Our FXIII concentration (100 nM) is within the 
physiological range of 86-173 nM [54].  After 5 min incubation at 37 °C, clotting was initiated 




13.5 mM, to exceed the citrate in plasma) in the borate buffer, resulting in a 1:4 dilution of the 
stock plasma. Clots were incubated for 2 h at 37 °C in closed microfuge tubes, rinsed with 
deionized H2O, and dehydrated in the presence of increasing (10 – 0%) concentrations of 
ethanol and dried with hexamethyldisilazane. The samples were next sputter-coated with Au-Pd 
and imaged using a Zeiss Supra 35 electron microscope.  
Since we aimed to study FXIIIA-mediated crosslinking of the fibrin clots, no 
glutaraldehyde (a chemical crosslinking agent) was used to stabilize the samples. Undiluted 
plasma clots suffered great deformation during drying and were too dense. A 1:4 dilution of the 
plasma (and hence, endogenous fibrinogen) resulted in thinner, more suitable SEM samples that 
allowed for adequate comparisons between exogenous FXIIIA variants.  These experiments were 
performed in duplicate. 
 
MDC crosslinking SDS-PAGE based activity assay – In order to compare activities of 
proteolytically and nonproteolytically activated FXIIIA, a series of MDC crosslinking assays 
was performed. For proteolytic activation, 1 µM FXIIIA was incubated in TBS with 30 nM 
recombinant human thrombin and 4 mM CaCl2 for 30 min at 37 °C, followed by addition of 760 
nM thrombin inhibitor PPACK. Nonproteolytic activation was achieved by 30 min incubation of 
1 µM FXIIIA in TBS in the presence of 100 mM CaCl2. 
Recombinantly expressed fibrinogen gC (βγγ-425) was used as a glutamine donor (Q-
substrate). gC (5 – 40 µM final) was preincubated for 5 min at 37 °C with a lysine mimic MDC 
(K-substrate, 1 mM final, from a 20 mM stock solution in methanol) in TBS containing CaCl2 (4 
– 100 mM final concentration). The crosslinking was initiated by addition of activated FXIIIA 




addition of reducing sample loading buffer, followed by 3 min of boiling. Samples were resolved 
using SDS-PAGE on 15% gels. Prior to Coomassie blue staining, the gels were photographed 
under UV light. The different MDC assay series were performed three independent times with 
comparable results obtained each time.   
 
Continuous spectrophotometric kinetic assay – In this assay adapted from de Macedo et al. 
[55], FXIIIA incorporated chromogenic K-substrate N,N-dimethyl-1,4-phenylenediamine 
(DMPDA) into a Q-substrate K9-peptide. The reaction progress was monitored by an increase in 
absorbance at 278 nm resulting from an anilide functionality of the crosslinked product. 
Nonproteolytic and proteolytic activation were performed as described for the MDC assay, 
except that FXIIIA was 4 µM in the activation mix. K9-peptide (46 – 1386 µM final) was 
preincubated with DMPDA (700 µM final, from a 100 mM stock solution in methanol) in the 
borate buffer with 4 or 100 mM of CaCl2 for 5 min at 37 °C. The reaction was initiated by 
addition of activated FXIIIA (final concentration 1 µM). Reaction velocities were determined 
over the initial part of the absorbance curve. An i = 8940 M−1 cm−1 [55] was applied to convert 
absorbance to µM of crosslinked product. Less than 15% of both Q and K substrates reacted in 
the initial linear region of the absorbance curves. Velocities in µM min−1 were fitted to the 
Michaelis-Menten equation as a function of the K9 concentrations using Kaleidagraph software 
(Synergy). The resultant Km and Vmax parameters represent apparent values and serve for 
comparison of nonproteolytically and proteolytically activated FXIIIA. The kinetic assays were 
performed in triplicate (three independent trials) for each activation condition. Results are 
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Fig. 1. Sedimentation properties and activation rate of FXIIIA under different conditions. A – 
Sedimentation profiles of FXIIIA studied by AUC: 2 µM FXIIIA was activated at 37 °C for 30 min 
nonproteolytically by 100 mM CaCl2 (trace I, green) or proteolytically by 3.5 NIH units/ml bovine 
thrombin in the presence of 4 mM CaCl2 (trace ii, purple). An additional sample of thrombin-activated 
FXIIIA contained 4 mM CaCl2 and 100 mM MgCl2 (trace iii, orange). Two independent samples were 
analyzed for each condition, with the same results.  
B – Dissociation progress of 2 µM FXIIIA in the presence of 4 (open blue circles) and 25 mM CaCl2 
(filled green circles). Graph on the left presents quantitative analysis of sedimentation velocity AUC data. 
The insert demonstrates fraction of soluble protein (estimated from absorbance at 280 nm) in samples of 4 
mM Ca2+-activated FXIIIA as a function of time. The panel on the right depicts AUC sedimentation 
profiles for the FXIIIA samples incubated in the presence of 25 mM CaCl2 for 30 min (dotted green line), 






Fig. 2. Effect of the rate of FXIIIA proteolytic 
activation on fibrin crosslinking. 
A – 1 µM recombinant FXIIIA AP variants were 
incubated with 30 nM recombinant human 
thrombin at 37 °C. Aliquots were withdrawn at 
denoted time points and thrombin was inhibited 
with 760 nM PPACK. The samples were then 
subjected to SDS-PAGE on 8% gels. FXIIIA AP 
cleavage resulting in a 4 kDa molecular weight 
loss could then be followed by monitoring the 
appearance of a 79 kDa band. 
B – Fibrin crosslinking by FXIIIA AP variants. 1 
mg/ml human FXIII-free fibrinogen was 
combined with a recombinant FXIIIA AP-variant 
(50 nM) at 37 °C, and crosslinking was initiated 
by addition of 12 nM recombinant human 
thrombin and 2.5 mM CaCl2. At each denoted 
time point, the reaction was stopped by addition 
of reducing sample loading buffer and boiling. 
The samples were resolved via SDS-PAGE (8% 
gel). Fibrinogen chains Ag, Bく, け, HMW (high 
molecular weight crosslinks), and け–け crosslinks 
are annotated. *  symbol denotes the earliest 
detection of HMW species during the course of 






Fig. 3. Scanning electron microscopy of fibrin clots in the presence of FXIIIA AP variants. 
100 nM FXIIIA AP variants were combined with plasma from FXIIIA-deficient mice (final dilution of 
plasma was 1:4). Control samples were made without FXIIIA (FXIIIA −). Clotting was initiated by 
addition of 2.1 NIH units/ml bovine thrombin and 13.5 mM CaCl2. lots were formed for 2 h at 37 °C 
and prepared for SEM as described in Materials and Methods. For each FXIIIA AP variant, two clots 
were studied, with essentially the same results. Each set of clots (FXIII −, W34, V34, and L34) was 
formed using plasma obtained from the same mouse. Shown are representative SEM photographs at two 
magnifications: 10,000x (left) and 20,000x (right), scale bars are 2 µm. Note that during the SEM sample 
preparation process, the fixative agent glutaraldehyde was not included to avoid artificial protein 
crosslinking. As a result, the FXIIIA−  clots were significantly flattened during the dehydration process.  






Fig. 4. Transglutaminase activity of FXIIIA under different conditions. 
A – Spectrophotometric kinetic assay. Glutamine donor K9 peptide was preincubated with the lysine 
mimic DMPDA at 37 °C for 5 min, and the crosslinking reaction was initiated by addition of 1 µM 
FXIIIA° ,high (green circle) or FXIIIA* (purple circle). The reaction was followed by an increase in 
absorbance at 278 nm due to formation of the anilide crosslinked product. The plot represents Michaelis-
Menten fits of the initial reaction velocities as function of the K9 concentration. Apparent Km and Vmax 
resulting from the fits are shown in the table insert. Values are presented as mean ± SD (N=3). 
B – MDC crosslinking SDS-PAGE based assay. Recombinant fibrinogen gC (βγγ-425) was preincubated 
with 1 mM MDC at 37 °C for 5 min. The crosslinking reaction was initiated by addition of 100 nM 
FXIIIA° ,high or FXIIIA*. Reaction aliquots were withdrawn at 1 – 7 min and quenched by addition of 
reducing sample buffer and boiling. The time point samples were loaded on 15% SDS-PAGE side by side 
for FXIIIA* (triangles) and FXIIIA°,high (circles). Two gels were run (1 – 4 and 5 – 7 min time points). 




stained gel pair from panel iii demonstrating absence of gC–gC conjugation. FXIIIA* was always 
preactivated in the presence of 4 mM CaCl2, and FXIIIA°
,high – in the presence of 100 mM CaCl2. 
Concentrations of gC and CaCl2 in the crosslinking reaction mix are annotated on the right.  
